Credit Suisse’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.61M | Buy |
141,343
+921
| +0.7% | +$22.8K | ﹤0.01% | 1681 |
|
|
2023
Q4 | $4.4M | Sell |
140,422
-8,920
| -6% | -$213K | ﹤0.01% | 1411 |
|
|
2023
Q3 | $3.11M | Sell |
149,342
-25,322
| -14% | -$688K | ﹤0.01% | 1557 |
|
|
2023
Q2 | $4.18M | Sell |
174,664
-30,148
| -15% | -$670K | ﹤0.01% | 1454 |
|
|
2023
Q1 | $3.85M | Buy |
204,812
+4,132
| +2% | +$78.7K | ﹤0.01% | 1484 |
|
|
2022
Q4 | $3.19M | Buy |
200,680
+23,111
| +13% | +$361K | ﹤0.01% | 1604 |
|
|
2022
Q3 | $2.9M | Sell |
177,569
-11,168
| -6% | -$181K | ﹤0.01% | 1602 |
|
|
2022
Q2 | $2.66M | Buy |
188,737
+18,175
| +11% | +$339K | ﹤0.01% | 1706 |
|
|
2022
Q1 | $4.13M | Sell |
170,562
-6,099
| -3% | -$148K | ﹤0.01% | 1596 |
|
|
2021
Q4 | $4.12M | Sell |
176,661
-64,933
| -27% | -$1.31M | ﹤0.01% | 2183 |
|
|
2021
Q3 | $4.01M | Buy |
241,594
+114,340
| +90% | +$2.2M | ﹤0.01% | 2241 |
|
|
2021
Q2 | $3.1M | Sell |
127,254
-19,376
| -13% | -$437K | ﹤0.01% | 2489 |
|
|
2021
Q1 | $3.78M | Sell |
146,630
-1,489
| -1% | -$65.5K | ﹤0.01% | 2308 |
|
|
2020
Q4 | $7.92M | Buy |
148,119
+8,091
| +6% | +$402K | ﹤0.01% | 1745 |
|
|
2020
Q3 | $5.78M | Sell |
140,028
-159,025
| -53% | -$6.87M | ﹤0.01% | 1697 |
|
|
2020
Q2 | $14.5M | Buy |
299,053
+193,958
| +185% | +$9.31M | 0.01% | 1107 |
|
|
2020
Q1 | $4.44M | Sell |
105,095
-87,411
| -45% | -$3.6M | ﹤0.01% | 1613 |
|
|
2019
Q4 | $8.23M | Sell |
192,506
-37,437
| -16% | -$1.63M | 0.01% | 1527 |
|
|
2019
Q3 | $8.28M | Buy |
229,943
+120,375
| +110% | +$3.65M | 0.01% | 1423 |
|
|
2019
Q2 | $2.93M | Buy |
109,568
+19,938
| +22% | +$509K | ﹤0.01% | 2169 |
|
|
2019
Q1 | $2.41M | Sell |
89,630
-2,236
| -2% | -$52.2K | ﹤0.01% | 2242 |
|
|
2018
Q4 | $1.49M | Buy |
91,866
+16,667
| +22% | +$324K | ﹤0.01% | 2469 |
|
|
2018
Q3 | $1.56M | Sell |
75,199
-25,996
| -26% | -$409K | ﹤0.01% | 2538 |
|
|
2018
Q2 | $1.54M | Buy |
101,195
+19,910
| +24% | +$355K | ﹤0.01% | 2677 |
|
|
2018
Q1 | $1.83M | Sell |
81,285
-2,200
| -3% | -$60.9K | ﹤0.01% | 2500 |
|
|
2017
Q4 | $2.52M | Sell |
83,485
-141,500
| -63% | -$4.52M | ﹤0.01% | 2258 |
|
|
2017
Q3 | $8.47M | Sell |
224,985
-42,395
| -16% | -$1.38M | 0.01% | 1355 |
|
|
2017
Q2 | $7.46M | Sell |
267,380
-74,366
| -22% | -$2.22M | 0.01% | 1379 |
|
|
2017
Q1 | $11.7M | Buy |
341,746
+127,125
| +59% | +$4.49M | 0.01% | 1128 |
|
|
2016
Q4 | $6.19M | Buy |
214,621
+118,496
| +123% | +$3.13M | 0.01% | 1503 |
|
|
2016
Q3 | $3.06M | Sell |
96,125
-86,412
| -47% | -$2.93M | ﹤0.01% | 2052 |
|
|
2016
Q2 | $5.93M | Buy |
182,537
+37,599
| +26% | +$1.26M | 0.01% | 1508 |
|
|
2016
Q1 | $4.05M | Buy |
144,938
+68,408
| +89% | +$1.49M | ﹤0.01% | 1681 |
|
|
2015
Q4 | $2.73M | Buy |
76,530
+10,920
| +17% | +$385K | ﹤0.01% | 2054 |
|
|
2015
Q3 | $2.17M | Sell |
65,610
-103,282
| -61% | -$4.3M | ﹤0.01% | 2197 |
|
|
2015
Q2 | $7.07M | Buy |
168,892
+78,777
| +87% | +$3.05M | 0.01% | 1469 |
|
|
2015
Q1 | $2.94M | Sell |
90,115
-8,374
| -9% | -$288K | ﹤0.01% | 2077 |
|
|
2014
Q4 | $3.13M | Sell |
98,489
-218,140
| -69% | -$6.19M | ﹤0.01% | 2150 |
|
|
2014
Q3 | $7.84M | Sell |
316,629
-52,721
| -14% | -$1.23M | 0.01% | 1445 |
|
|
2014
Q2 | $8.34M | Buy |
369,350
+78,736
| +27% | +$1.64M | 0.01% | 1537 |
|
|
2014
Q1 | $7.07M | Buy |
290,614
+1,101
| +0.4% | +$27.9K | 0.01% | 1492 |
|
|
2013
Q4 | $7.23M | Buy |
289,513
+201,959
| +231% | +$4.76M | 0.01% | 1518 |
|
|
2013
Q3 | $2.41M | Sell |
87,554
-34,746
| -28% | -$726K | ﹤0.01% | 2235 |
|
|
2013
Q2 | $2.22M | Buy |
+122,300
| New | +$1.68M | ﹤0.01% | 2191 |
|
Other funds holding ACAD
BBA
RI
EC
Credit Suisse's ACAD Position: Q1 2024 in Review
Credit Suisse increased its Acadia Pharmaceuticals (ACAD) stake by 0.66% in Q1 2024, buying an estimated $22.8K and bringing the position to 141,343 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1681.
Credit Suisse first reported a position in ACAD in Q2 2013 and has held it in 44 quarters since. The position peaked at $14.5M in Q2 2020. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.
- Credit Suisse held 141,343 shares of Acadia Pharmaceuticals worth $2.61M as of Q1 2024.
- Credit Suisse bought 921 Acadia Pharmaceuticals shares in Q1 2024, an estimated $22.8K.
- Acadia Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1681 holding.
- Credit Suisse first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Acadia Pharmaceuticals position peaked at $14.5M in Q2 2020.
- 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.